Inhalation Sciences AB secures long-term financing of operations
(Stockholm, Sweden, 24 May 2022) Inhalation Sciences AB has received a credit line from a consortium of lenders of up to SEK 10 million, giving the company increased scope to finance its operations and growth over the next 12-14 months.The company's chairman of the board, Daniel Spasic, is among the lenders through his American company S-Growth Capital LLC, with a loan of SEK 1 million. The company estimates that the credit line, together with self-generated funds, will be to sufficient to finance ISAB in line with its growth strategy for the coming 12-14 months. Daniel Spasic,